Tapinarof Cream for Adults and Children with Atopic Dermatitis—Efficacy by Race and Fitzpatrick Skin Type in Two Phase 3 Randomized Clinical Trials

Abstract Introduction Patients with atopic dermatitis (AD) and skin of color have heterogeneous presentations and treatment outcomes, however, they are underrepresented in trials. In the ADORING 1 and 2 phase 3, 8-week randomized trials, tapinarof cream 1% once daily (QD) demonstrated superior effic...

Descripció completa

Dades bibliogràfiques

Autors principals:	Andrew F. Alexis, Leon Kircik, Raj Chovatiya, Zakiya P. Rice, Weily Soong, Tina Bhutani, Philip M. Brown, Stephen C. Piscitelli, David S. Rubenstein, Anna M. Tallman, April W. Armstrong
Format:	Artigo
Idioma:	Inglês
Publicat:	Adis, Springer Healthcare 2025-07-01
Col·lecció:	Dermatology and Therapy
Matèries:	Tapinarof cream 1% once daily Aryl hydrocarbon receptor agonist Atopic dermatitis Skin of color Diverse population Fitzpatrick skin type
Accés en línia:	https://doi.org/10.1007/s13555-025-01489-w
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!